1/61
Looks like no tags are added yet.
Merikangas et al., 2007
epidemiological study (large n)
(disadvantages): cross-sectional; recall bias; based on DSM criteria
Findings:
BD ~ 1.4%
BDI ~ 1.0%
BDII ~ 1.1%
Subthreshold ~ 2.4%
McIntyre, 2009
Narrative review (risk of selection bias)
Findings:
~ >40% of patients are dissatisfied with/ treatment
Primarily regarding: weight gain and relapse prevention
Goodwin et al., 2011
Reviews efficacy for pharmacological treatment of acute mania
Systematic review and meta-analysis
commissioned by BAP guidelines
Findings:
Top ranked: RIS, OLZ, QTP
emphasizes treatment variability (effect size and tolerability differ across patients)
ONS, 2014
Survey outcome
Higher prevalence in women
only 1/3 of individuals with a common mental health disorder receive treatment
(disadvantages) self-report; cross-sectional
Papakostas et al., 2016
findings:
Patient preferences affect treatment outcome
Cipriani et al., 2018
meta-analysis 21 ADM
Treatment for acute major depression
ADM outperform placebo - modest effect size
Disadvantages:
Side effects reduce acceptability
withdrawal inflates placebo
trials did not test blinding integrity
Run-in design
Moncrieff, 2001
Drug-centered model
Active placebo reduces ADM efficacy
Nanni et al., 2012
Meta-analysis
Trauma reduces treatment outcome
Increases relapse rate
associate w/ chronic and persistent sx
greater impairment Ne
Nemeroff et al., 2003
RCT;
CBT vs SSRI
Trauma as a moderator
Disadvantage: small n, 1 ADM and 1 psychotherapy tested.
McIntyre et al., 2023
Systematic review.
30-50% of pts have TRD
TRD: research concepto; failed response after two or more adequate trials in a curren episode. Associate with poorer outcome,s higher mortality rates and lower quality of life of life.
Difficult-to-treat depression: Reflects the complexity, chronicity and impact of this diagnosis. Emphasize sperosnalized treatment. Accordance to Rush et al., 2018 mode. )
Cleare et al., 2015 BAP guidelines
Strategies for no response:
Dose increase
poor evidence for SSRIs
Switching
Better evidence; especially early switching
Combination (2 adm) or Augmentation (ADM + another)
Relapse and recurrence risks
Low risk
High risk
high recurrent risk
Low risk
risk‑stratification categories
Single episode
Continue treatment 6–9 months after remission
High risk
risk‑stratification categories
More than one episode
Continue treatment ≥1 year
High recurrent risk
Risk stratification categories
5+ episodes, or 2 episodes in 2 years
Consider long‑term maintenance treatment
Rush et al., 2004
STAR-D Methods and Results
12-14 week large scale longitudinal study to evaluate real-world effectiveness of depression treatment.
the largest and most methodologically rigorous study of sequential treatment in MDD, demonstrated that remission rates declined markedly with each treatment step
Level 1: Citalopram ~ 33-37% remission
Level 2: switch or augment / CBT ~ 25-31%
Level 3: switch or augment ~ 14%
Level 4: switch or augment ~ 14%
Important highlights:
Remission decreases with each treatment steps
This suggests that pharmacological stepping alone is insufficient for a substantial proportion of patients, highlighting the need for alternative approaches."
early and aggressive intervention is essential
Disadvantages
no double-blinding (open label design)
open-label design and lack of placebo control limit the certainty of its conclusions, as expectancy effects and clinician bias cannot be ruled out
patient-prefrence
CBT in only lv 2
High dropout rates
no placebo
heterogeneous sample
Warden et al., 2007
Comprehensive review of finding from STAR-D
Unfavorable predictors:
med/psych comorbidities
chronic depression
poor functioning
long current episode
better remission:
white
fem
marreid
higher education level
higher incoe
employed
privat einsurance
findings:
CT was as effective as switching/augmentation
Relapse risk increases sharply w/ each step
early intervention matters (!!!)
individualized treatment (tolerability, patience preference, prior response, comobridties)
No major differences between primary and secondary care
TRD mechanism
no response
failure to sustain response
Unfavorable predictors according to Warden et al., 2007
med/psych comorbidities
chronic depression
poor functioning
long current episode
Sachs et al., 2003
STEP-BD
large-scale study to evaluate real-world effectiveness
Two pathways:
Standard care pathway
Follow usual guidelines (adjust, switch, combine, discontinue)
(adjust, switch, combine, discontinue)
Personalized care pathway
randomized into clinical pathways
protocol-driven
(disadvantages)
not randomized
medicines are heterogeneous
therapy trial - self selected
no control over treatment
weak causal interference
Bowden et al., 2011
Clinical implications
BD requires phase-specific interventions
ADM caution
specific risk - TAOI & MAO
ADM did not improve depression, did not speed recovery and did not increase switching
higher risk when not combined
psychotherapy improved recovery
patients receiving psychotherapy were 1.58 times more likely to recover.
Recurrence occurs in approximately 50% of patients
predictors:
rapid cycling
early onset
residual symptoms
symptom abuse
comorbid anxiety
BD1
sleep disturbance diminishes functioning
Predictors of relapse in BD (Bowden et al., 2011)
rapid cycling
early onset
residual symptoms
comorbid anxiety
BD1
sleep disturbance diminish functioning
Goodwin & Jamison et al., 2007
Phases of Treatment
Acute - 6-12 w - Until response or remission (ideally)
Continuation - 7- 13 months - on-going
maintenance - prevents futures episodes (maintenance - after remission; continue stability) (prophylaxis - prevent new ep)
Miura et al., 2013
Meta-analysis and Review
Li and QTP good evidence to prevent relapse
Li - non-enriched samples
QTP - enriched samples
(can combine if with fluoxetine)
Li loweres suicide risk
Li maintenacne 0.6-0.8 mmol/l
Li et al., 2015
Systematic Review and Meta-analysis
CBT is the most evidence-based form of treatment
disadvantages:
Doesn’t account for biological aspects
used for less severe cases
requieres motivation and cognitive capacity
may overlook trauma-based processes
Structure of CBT
This therapy is:
present focused
directive and structured
time limited
aim - build self-help skills
Cognitive mechanisms
automatic thoughts - spontaneous and accessible and believable
intermediate thoughts - rules of living, conditional (“if…then…”)
Cognitive maintenance of depression
Vulnerability - dysfunctional scheme
Trigger events activate this (turning it into a vicious cycle)
Leads to:
negative thoughts
cognitive distortions
behviaoural responses
consequences
Antidepressant caution (Bowden et al., 2011)
specific risk - Tricyclic antidepressants and MAOIs
did not improve bipolar depression
did not speed recovery
higher risk when not combined
Psychotherapy improved recovery (1.58 x more likely)ja
Jaeger et al., 2006
Cross-sectional neuropsychological evaluation of MDD
6 month follow-up
Depression patients exhibited cognitive impriment when compared to HC
core issues: working memory, processing speed, executive functioning
Issues persisted after mood improved (!!)
cognitive impairment predicted functional outcome better than symptom severity.
Disadvantages:
small n (hospitalized n)
cross-sectional
Martínez-Arán et al., 2007
Cross-sectional neuropsychological evaluation of BD.
Studies further demonstrate that individuals with bipolar I disorder underperform when compared to healthy controls (Burdick et al., 2011)
core issues: working memory, attention, executive functioning
Miskowiak et al., 2018
Bipolar cognitive assessment
2-3 months after an acute episode (may be assessed every 5 years if impairment is detected)
Initial evaluation: SCIP & COBRA (provide a quantification of verbal learning, working memory and processing speed while also recounting subjective experience of his cognitive difficulties, respectively)
Evaluate if it is illness-related
That is not: secondary to medication, comorbidity or unhealthy life-style, due to organic brain disorder or dementia.
Address secondary causes if so.
What to do: recommendations for patients and their relative, Encourage compensation strategies, support & adjustments of expectation
•Track cognition over time, ideally at least every 5 years or when there is a reason to anticipate an assessment
Legemaat et al., 2022
meta-analysis of RCTs for CRT in MDD
preliminary findings
small-to -moderate effects
no evidence of log-term benefit
Effects strongest for processing speed and verbal learning
disadvantages:
small numbers of high-quality RCTS
small samples
CRT protocols varied
underpowered trials
cognitive impairment
Impairment in mental processes involved in learning, retrieving info, understanding , planning, resolving and making decisions.
They are heterogeneous across patients and are hard to discern from illness or medication effects.
Samamé et al., 2023
Meta-analysis of CRT for Bipolar
small to moderate effects
improvements: attention, executive functioning memory
Minimal effects on mood symptoms
No examination of psychosocial functioning (major gap)
CRT is safe and well-tolerated
(disadvantages )
Very few RCTs
No functional outcomes (work, social functioning)
BD samples highly heterogeneous (I vs II, euthymic vs symptomatic)
CRT protocols inconsistenC
Cognitive Remediation Therapy
Cognitive impairment is an underrated persistent issue within affectivee disorders.
(Millet & Burdick et al., 2021)- resiliency course
This type of of therapy targets persistent cognitive deficiencies.
Findings are preliminary (we need larger (RCTs)
Promotes metacongition (knowledge and regulation) and emphasizes strategy use
there is promising evidence, yet no replication Ani
Animal models
Are used for exploratory and developmental reasons, because regulations demand them to fulfill requirements, to investigate underlying mechanisms and are demanded by the public.
Have a low-construct validity (extent to which a tolls measures a theoretical/abstract concept).
validity of a procedure depends on the objectives of the experiment.
Disadvantages:
Do not capture subjective epxiernces
Psychological disorders are language based
No biormarkers
Cross-sectional analysis
Treatment-Resistant Depression
Focuses on an acute biological
Research definition
Failure of two or more adequate trials in current episode
Approach is many biomedical with a categorical endpoint (remission or not)
Difficult-to-treat Depression
It is a collaborative concept, representing a chronic illness model
Approach: biopsychosocial, capability approach, recovery movement, optimizing symptom control, minimizing impact of symptoms.
Endpoint is dimensional
Uses a 3D assessment model (McAllister-Williams et al., 2020):
person factors (genetics, trauma, etc)
illness factors (early onset, chronicity, comorbidity)
treatment factors (previous response, number/type, etc.)
McCloud et al., 2015
Meta-analysis and systematic review.
RCT of single-dose IV trials in bipolar depression
Rapid, large antidepressant effect
Strongest evidence: 24 - 72 hours
effect persists but weakness over days
works in ppl who failed multiple ADM
consistent across trials
RElevance:
TRD is not biologically “fixed” - rapid effect
glutamate and synaptic plasticity matter, shifting research away from sertononi-only networks
Disadvantages
very small RCTs
short follow-up
heterogeneous TRD definition
restricted populations
publication bias
Disadvantages
effect is rapid and short-lived
conclusions are limited due to small amounts of usable data
small n - underpowered
no active placebo
heterogeneous deign
Evidence base is too small and too low-quality to draw reliable conclusions
Zarate et al., 2006
RCT of a single-IV ketamine dose TRD
Rapid antidepressant effect lasting up to 7 days
relevance:
rapid effect is clinically significant demonstrating TRD is modifiable
glutamatergic mechanisms can produce rapid mood improvement
Proof-of-concept
Disadvantages
effect is rapid and short-lived
meta-analysis (Krystal et al., 2020)
FDA, 2011
Systematic review & meta-analysis
Biological efficacy of ECT is superior than Sham (ECT placebo) and medication.
ECT is more effective than meds; especially in severe depression
Support ECT as most effective acute treatment
Disadvantages:
older trials included
variation in ECT techniques
short follow-ups
Nordenskjold et al., 2012
Large observational cohort study
Predictors of ECT response:
older adults
more severe depression
psychosis
personality disorders
inpatients respond better than outpatients
Disadvantages:
observational (confounding factors; cannot infer causality)
limited generalizability
Jelovac et al., 2013
Systematic review & meta-analysis
Relapse rates for ECT
~ 27% at 3 months
~ 51% at 12 months
~ 50% at 24 months
Highly effective acutley but relapse is a major issue.
Dowlati et al, 2010
systematic review and meta-analysis of observational cohort studies
MDD has been associated with higher levels of ls of IL-6b and TNF-alpha
Elevations are seen even outside depressive episodes, suggesting trait‑level inflammation.
It is stipulated that elevation precedes depression (Findings imply inflammation may precede or increase vulnerability to depression)
Relevance
may be biomarkers
provides rational for a biological mechanism
provides rationale for immune-modulating treatments
(Disadvantages):
observational biomarker studies of serum-plasma- cannot infer causality
high heterogeneity
peripheral cytokines may not reflect central inflammation
Solmi et al., 2021
Systematic review and meta-analysis of observational case-control studies
IL-6 is elevated in BD across depression, mania and euthymia.
Immune abnormalities are present outside mood episodes
Relevance:
IL-6 is potentially a trait marker
differentiate between BD from MDD (Bd shows more persistent inflammation)
provides rationale for immune-modulating treatments
disadvantages:
observational biomarker studies - can not infer causality
high heterogeneity
peripheral markers may not reflect central inflammation
Reiger et al., 1990
US epidemiological study
Bipolar patients had approximately 6 times higher odds of any substance use disorder compared to the general population.
Elevated rates also seen in MDD, but much lower than bipolar.
Alcohol, drug, and polysubstance misuse all markedly over‑represented.
Relevance:
establishes how common SUDs are in MD
suggest comorbidity is not incidental - major clinical feature
Provides the epidemiological foundation for why treatment is more complex in bipolar disorder.
Disadvantages:
cross sectional - cannot infer causality
DSM 90s critera
does not capture longitudinal course
self-report
Merikangas et al., 2008
20‑year prospective cohort study
Manic symptoms predicted later:
a fourfold increase in the risk of alcohol dependenc
a fivefold increase in cannabis misuse
and an elevenfold increase in benzodiazepine abuse.
RElevance:
suggest that mood dysregulation increases vulnerability to addiction
Supports shared neurobiological mechanisms (
Helps explain why bipolar disorder has high relapse rates and treatment resistance when SUD is present.
Disadvantges:
Observational → cannot prove causality.
Swiss cohort → may limit generalisability.
Substance use was partly self‑reported.
Does not fully separate effects of early environment or genetics.
Dalton et al., 2003
Bipolar patients with comorbid drug use disorder had significantly higher rates of suicide attempts than those without drug use.
relevance:
Demonstrates that SUD is not just comorbidity — it worsens prognosis.
Supports the argument that comorbid SUD → higher risk, more instability, more severe episodes.
Disadvantages:
Cross‑sectional → cannot determine directionality.
self-reported - recall bias
Does not differentiate between types of substances.
self-medication hypothesis
According to this hypothesis, individuals with a mood disorder may employ substances as a coping mechanism to address their mood dysregulation or symptoms.
For instance:
alcohol → anxiety or agitation
cananbis → calm mood
sedatives → distress
stimulants → counter depression re
Challenge of hypothesis: Although SUD worsen long-term instability in BD, a study shows (Stakowski et al., 2000) that 75 % of people with bipolar disorder do not change their alcohol consumption during a manic episode.
Reward Pathway
Possible underlying mechanism of addiction and affective disorders
Addictive substances dysregulate reward-learning mechanisms by generating dopamine signals larger and faster than natural rewards.
Possible effects of comorbidity SUD in affective disorders
higher risk of suicide
poorer adherence to treatment
poorer outcomes
higher relapse rates
Judd et al., 2002, 2003
Depressive symptoms overwhelmingly dominated the symptomatic periods in both bipolar I and bipolar II disorder.
In bipolar I, 67% of symptomatic weeks were depressive
In bipolar II, depressive symptoms accounted for 94% of symptomatic weeks
Methodological challenges of psychotherapy
There are in asymmetry in reporting.
Greatest benefits seem to derive from the therapeutic alliance.
Therapy can not be blinded and there may always be an expectancy effect that a waitlist comparator can not account for.
While ADM have mandatory reports of harm, therapy doesn’t when it can lead to increased instability.
Colom et al., 2003, 2009
2 RCTs done by the same group using the Barcelona program (21 sessions) . Structured: illness awareness, prodrome detection and adherence to a long-term trajectory.
5 year follow up
Findings:
diminshed relapse (especially manic)
prevented manic episodes
diminished hjopsitalisations
Relevance
effects are durable - persisting up to 5 years
strong evidence for pyschoeducation
Reinares et al., 2013
Narrative review comparing psychosocial interventions for Bipolar.
Best - structured group psychoeducation
long-lasting effect ts
CBT - most effective to prevent depressive spidoses
IPSRT - useful in acutely ill patients
may increase time of remission
Functional remediation - improves social and cognitive functioning
Relevance
phase-specific interventions
mehcnaism-specific eiinterventions
highlight that psychosocial interventions target different pathway s
Disadvantages
NOT a meta-analysis - selection bias
effects depend on illness stage and polarity
heterogenous
small n
Goodwin et al., 2022
Double-blinded clinical trial
single psychedelic session (psilocybin)
Active placebo
Findings:
25 mg psilocybin produced significantly greater reductions in MADRS at 3 weeks vs 1 mg.
26% were in remission at 12 weeks
Effects were strongest in the first 3–6 weeks and attenuated over time.
Adverse events were mostly mild/moderate and transient (headache, nausea, transient anxiety).
(disadvantage)
blindings is questionable as 25 mg is probably recognizable (1 mg)
Psychological support was standardised but still a potential confound.
Industry‑sponsored (COMPASS Pathways).
Excluded people with significant comorbidities → limits generalisability.
highly selected sample
Carhart-Harris et al. 2017
Open-label trial with 6 month follow-up
Evaluated safety and efficacy of psilocybin with psychological support in 20 patients with treatment-resistant depression
Key Results
Safety & Tolerability: The treatment was well tolerated with no serious or unexpected adverse events. Transient anxiety during onset was common. [1, 2, 3]
Short-Term Efficacy: Marked reductions in depressive symptoms occurred rapidly and lasted through the first 5 weeks (effect size Cohen's d = 2.2 at week 1 and 2.3 at week 5, p < 0.001). [1, 2]
Response and Remission: At 5 weeks post-treatment, 9 out of 20 patients (45%) met criteria for a clinical response, and 4 (20%) achieved complete remission. [1, 2]
Long-Term Follow-Up: Sustained positive improvements and reduced symptom scores remained apparent at the 3-month and 6-month evaluation marks for a subset of responders. [1, 2]
Produced 33% of remission at 6 months follow-up
Some participants maintained substantial, sustained improvement.
Qualitative reports suggested increased emotional openness and psychological flexibility.
Limitations
open-label
no control group
highly selected motivated patients
Intensive psychological support → unclear contribution of therapy vs drug
these estimates are inflated by the absence of controls and high expectancy effects.”
El
Elawad et al., 2021
Observational cohort-study
Predictors of higher response rates of ECT
psychotic features
old-age (especially w/ psychotic features)
severe depression
TRD
suicidality
disadvantages:
observational - cannot infer causality
heterogeneous sample
Wang et al., 2023
large prospective cohort study
Childhood maltreatment (any type) is significantly associated with the risk of depression in late-life depression.
High quality population-based evidence
Supports trauma-informed models
Disadvantages:
self-report (recall bias)
cannot infer causality
UK - cannot generalize
confounders
Barnes et al., 2012
Retrospective cohort study
Depression ate any stage of life increases the risk of dementia - may be prodromal to dementia
Depression may be hard to diagnose - avoid polypharmacy (anticholinergic burden: cumulative negative effect of multiple medicines block ACTh - age related sensitivity)
Disadvantages:
depression measured symptom questionnaire
cannot separate cause from prodrome
confounding
Anticholinergic burden
Anticholinergic side effects overlap with depressive symptoms, making the clinical picture messy. In older adults, depression can be difficult to diagnose because anticholinergic burden from multiple medications can mimic or worsen depressive and cognitive symptoms. Age‑related cholinergic vulnerability means even moderate polypharmacy can produce clinically significant cognitive slowing, apathy, and confusion.
psychedelics mechanism
activate 5‑HT2A receptors on cortical pyramidal neurons, increasing their excitability and producing a glutamate surge in the prefrontal cortex. This stimulates AMPA receptors and triggers BDNF release and mTOR signalling, which together promote synaptic plasticity.
5HT2A receptors → cortical pyramidal nuerons → producing a glutamate surge → stimulates AMP receptors → trigger BDNF release → promote synaptic plasticity
ketamine mechanism
blocks NMDA receptors on GABA interneurons, reducing inhibition and causing a glutamate surge in the prefrontal cortex. This enhances AMPA receptor activity and initiates BDNF release and mTOR signalling, leading to rapid increases in synaptic plasticity.
blocks NMDA on GABA interneurons → reduce inhibition → producing a glutamate surge → stimulates/enhances AMP receptors → trigger BDNF release → promote synaptic plasticity